SG
VERA icon

Sankala Group’s Vera Therapeutics VERA Stock Holding History

Sankala Group’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.38K Hold
61
– – ﹤0.01% 478
2025
Q4 		$2.49K Buy
+61
New +$2.17K ﹤0.01% 486

Other funds holding VERA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sankala Group's VERA Position: Q1 2026 in Review

Sankala Group held its Vera Therapeutics (VERA) position steady in Q1 2026 at 61 shares worth $2.38K. The position accounts for ﹤0.01% of the portfolio, ranked #478.

Sankala Group first reported a position in VERA in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.49K in Q4 2025. 229 funds tracked by Wall St. Rank hold VERA as of Q1 2026.

  • Sankala Group held 61 shares of Vera Therapeutics worth $2.38K as of Q1 2026.
  • Sankala Group left its Vera Therapeutics share count unchanged in Q1 2026.
  • Vera Therapeutics made up ﹤0.01% of Sankala Group's portfolio in Q1 2026, its #478 holding.
  • Sankala Group first reported a position in Vera Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Sankala Group's Vera Therapeutics position peaked at $2.49K in Q4 2025.
  • 229 funds tracked by Wall St. Rank held Vera Therapeutics as of Q1 2026.

Based on Sankala Group's 13F filing for Q1 2026, filed 31 Mar 2026.